AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
CeriBell, Inc.
Video analysis: CBLL
All videosNo video analysis for this stock yet. Request one from our team.
News: CBLL
BlackRock Inc. Acquires New Holdings in CeriBell, Inc. $CBLL
BlackRock Inc. bought a new position in shares of CeriBell, Inc. (NASDAQ: CBLL) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 1,936,093 shares of the company's stock, valued at approximately $37,657,000. BlackRock Inc. owned approximately 5.10% of CeriBell as
Bank of America Corp DE Has $5.86 Million Position in CeriBell, Inc. $CBLL
Bank of America Corp DE boosted its holdings in CeriBell, Inc. (NASDAQ: CBLL) by 15.3% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 319,837 shares of the company's stock after acquiring an additional 42,340 shares during the
CeriBell Expands EEG Platform Beyond Seizures With Delirium, Pediatric Push
CeriBell NASDAQ: CBLL outlined its plans to expand its brainwave-monitoring platform beyond seizure detection, pointing to new products for delirium, pediatric patients and eventually stroke as it continues to build its hospital customer base.
CeriBell, Inc. (CBLL) Q2 2026 Earnings Call Transcript
CeriBell, Inc. (CBLL) Q2 2026 Earnings Call Transcript
Here's What Key Metrics Tell Us About CeriBell, Inc. (CBLL) Q2 Earnings
Although the revenue and EPS for CeriBell, Inc. (CBLL) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
CeriBell, Inc. (CBLL) Reports Q2 Loss, Tops Revenue Estimates
CeriBell, Inc. (CBLL) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to a loss of $0.38 per share a year ago.
CeriBell Q2 Earnings Call Highlights
CeriBell NASDAQ: CBLL reported second-quarter 2026 revenue growth of 33% as increased utilization at existing hospital accounts and continued customer additions supported results. The company also raised its full-year revenue outlook and outlined plans to commercially launch its delirium-monitoring solution later this year.
Ceribell Receives FDA Clearance for Advanced Epileptiform Abnormality Detection and Artifact Reduction for Its Cloud-Based Portal, Delivering Greater Precision for Critical-Care EEG Review
SUNNYVALE, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell” or the “Company”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for two new AI algorithm enhancements integrated directly into its existing cloud-based Neurology Portal: Epileptiform Abnormality Detection and Artifact Reduction.1 These new capabilities expand the clinical utility of the Ceribell Point-of-Care (POC) brain monitoring system, providing neurologists and bedside practitioners with an enhanced toolset for rapid, high-confidence electroencephalogram (EEG) assessment.
